Evidence map›Paper›PMID 33387035›Full record

ArticleJournal of cancer research and clinical oncology2021

Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study).

Fiorenza De Rose, Maria Carmen De Santis, Bruno Meduri, Ciro Franzese, Davide Franceschini, Pierfrancesco Franco, Nadia Pasinetti, Valentina Lancellotta, Patrizia Giacobazzi, Eliana La Rocca and 5 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Fiorenza De RoseRadiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milano, Italy.
Maria Carmen De SantisRadiotherapy Unit 1, Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Milano, Italy.
Bruno MeduriRadiation Oncology Unit, University Hospital of Modena, Via del pozzo71, 41124, Modena, Italy. brunomeduri@gmail.com.ORCID http://orcid.org/0000-0002-7588-9081
Ciro FranzeseRadiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milano, Italy.
Davide FranceschiniRadiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milano, Italy.
Pierfrancesco FrancoDepartment of Oncology, University of Turin, Turin, Italy.
Nadia PasinettiRadiation Oncology Service, ASST Valcamonica Esine and Brescia University, Brescia, Italy.
Valentina LancellottaDipartimento di Diagnostica per Immagini, UOC Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Radioterapia Oncologica ed Ematologia, Roma, Italia.
Patrizia GiacobazziRadiation Oncology Unit, University Hospital of Modena, Via del pozzo71, 41124, Modena, Italy.
Eliana La RoccaRadiotherapy Unit 1, Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Milano, Italy.
Elisa D'AngeloRadiation Oncology Unit, University Hospital of Modena, Via del pozzo71, 41124, Modena, Italy.
Laura LozzaRadiotherapy Unit 1, Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano, Milano, Italy.
Lorenzo LiviDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy.
Icro Meattini *Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy.
Marta Scorsetti *Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milano, Italy.
Breast Cancer Research Foundation · USUniversity of Modena and Reggio Emilia · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITHumanitas University · ITAzienda Ospedaliero-Universitaria Careggi · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeRandomized trials confirmed the efficacy and the safety of hypofractionated whole breast irradiation (HF-WBI) in patients with early-stage breast cancer. However, the role of HF-WBI in patients with DCIS after breast conserving surgery has not yet been clearly established in prospective randomized trials. The aim of this study was to evaluate if HF-WBI can be considered comparable to conventionally fractionated (CF)-WBI in DCIS patients. MATERIALS AND

methodsThe analysis included DCIS patients from four Italian centers treated with CF-WBI 50 Gy/25 fractions or HFRT 40.5 Gy/15 fractions, without tumor bed boost. A propensity score matching (PSM) analysis was performed using a logistic regression that considered age, grading, presence of necrosis, resection margin status and adjuvant endocrine therapy.

resultsFive hundred twenty-seven patients was included (367 in the CF-WBI-group and 160 in the HR-WBI group). After 1:1 matching, 101 patients were allocated to the CF-WBI-group and 104 to the HF-WBI group. No correlation was observed between the type of RT schedule and LRFS (HR 1.68, 95% CI 0.82-3.45; p = 0.152). After PSM, no statistical difference was observed between the two RT group (HR 1.11, 95% CI 0.40-3.04; p = 0.833), with 3- and 5-years LRFS rates of 100% and 97.9% for CF-WBI and 95.6% and 94% for HF-WBI.

conclusionA short course of radiation therapy seems to be comparable to CF-WBI in terms of clinical outcomes. These data support the use of hypofractionated schedules in DCIS patients, but considering the remaining uncertainties.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiation Dose HypofractionationRadiotherapy, AdjuvantRetrospective StudiesBreast cancerDuctal carcinoma in situHypofractionated radiotherapyMulticenter studyPropensity score matching

Identifiers

PMID33387035
PMCPMC11801928
OpenAlexW3114653921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.